At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Jason Westin, Director of Lymphoma Clinical Research at MD Anderson Cancer Center, presented the primary overall survival analysis of the phase 3 ZUMA-7 trial investigating axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomas. In this interview, he shares more with Oncology Data Advisor regarding the efficacy, safety, and future directions of this promising agent.
While the current standard of care for relapsed/refractory large B-cell lymphoma is high-dose therapy with autologous stem cell rescue, many patients do not respond to or cannot tolerate high-dose therapy. As a result, outcomes for second-line treatment remain poor. At the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, Dr. Frederick Locke of Moffitt Cancer Center presented the primary results of ZUMA-7, a phase 3 clinical trial investigating...
The FDA has approved axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for treatment of adult patients with large B-cell lymphoma (LBCL). Axicabtagene ciloleucel, also known as axi-cel, is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. It is indicated as a second-line treatment for patients who have already undergone first-line chemoimmunotherapy with no response or who have experienced relapse within 12 months of first-line chemoimmunotherapy. It is noted that axic...
Recently, the FDA approved axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. The approval was based on results from ZUMA-5, a phase 2 trial in which axicabtagene ciloleucel demonstrated a high rate of efficacy. In this interview, one of the study investigators, Julio Chavez, MD, of the Moff...
The FDA has granted accelerated approval to axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. An indolent form of non-Hodgkin lymphoma (NHL) that is not generally curable, FL is considered a chronic disease. Therefore, people living with FL often require second-line therapies after their di...
Large B-cell lymphoma is an extremely destructive, invasive subtype of non-Hodgkin lymphoma. Often, patients with this malignancy have undergone several treatments that have not worked. New therapeutic approaches are necessary for relapsed/refractory disease. A breakthrough personalized treatment, CAR T-cell therapy may be an option for patients with relapsed/refractory large B-cell lymphoma. Patients undergo a process called leukapheresis, in which a patient's blood is collected and put through...